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Background: Centella asiatica (C. asiatica) was previously reported to have anti-hyperglycemic effects in animal
diabetic model rats. However, its activity on organ and tissue level remains unstudied. Our study aims at exploring
the possible effects, C. asiatica extract and insoluble fiber has on carbohydrate absorption, insulin secretion, insulin
sensitivity and glucose utilization.
Methods: For primary evaluation of anti-hyperglycemic activity, we measured Fasting Blood Glucose and performed
Glucose Tolerance Test, in type 2 diabetic rats. To further study the pancreatic effect and glucose utilization, plasma
insulin concentration, insulin secreted from isolated rat islets and liver glycogen were assayed. Effect on
carbohydrate break down was assayed using intestinal disaccharidase enzyme, α-amylase inhibition assays and
Six-Segment study of the GI tract. Effect of C. asiatica on glucose absorption was studied by an in-situ, perfused,
intestinal model in rats and by glucose-fiber binding assay. Gastrointestinal motility was seen by a BaSO4 milk
traverse test. Additionally, a complete lipid profile assay, after a chronic study, was conducted.
Results: C. asiatica showed no significant change in insulin secretion in-vivo and in isolated rat islets. Additionally,
no effect of the extract was seen on liver glycogen deposition. Retarded glucose absorption was seen in the in-situ
perfused rat intestinal model at a dose. The extract was also found to inhibit action of both intestinal disaccharidase
and α-amylase. This was confirmed, yet again, via the Six Segment study, where sucrose digestion was found to be
inhibited throughout the length of the GI Tract. Significant glucose-fiber binding was demonstrated in the in-vitro
models. During the chronic study, body mass of C. asiatica treated Type 2 diabetic rats returned to normal and their
polydipsic and polyphagic conditions were also improved. Chronic treatment of C. asiatica also improved subject’s
lipid profile.
Conclusion: A combination of in-vitro, in-vivo and in-situ tests confirmed the anti-hyperglycemic activity
of C. asiatica and its tissue level mechanism. Further study is required to fully elucidate the effect this
extract or the active compounds have on the individual glucose transporters and the precise mechanism
of glucose-fiber binding.Background
In the last few decades, diabetes has established its pos-
ition as one of the world’s predominant endocrine dis-
order [1]. The number of people to be affected by this
disease by the year 2000 was estimated to be 171 mil-
lion, by World Health Organization [1]. Diabetes, by na-
ture, cannot be completely cured rather it has to be kept* Correspondence: ashraful_kabir@ymail.com
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reproduction in any medium, provided the orunder tight control [2]. This control might be achieved,
by modifying lifestyle, medications, diet, or a combin-
ation of all of these [3]. Many of the drugs currently in
use, are expensive and have adverse effects which, in
tandem, makes diabetes management even more difficult
[4]. Complementary and Alternative Medicines (CAM)
therefore have a large room to bring about improve-
ments in the current practices of diabetes management.
CAM is rapidly growing popular throughout the worldd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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than synthetic, patented drugs in the perspective of de-
veloping countries. A large segment of the population in
these countries are traditionally reliant on CAMs for
managing a multitude of disorders including, diabetes
[6]. However, evidences regarding efficacy of these ther-
apies are still sparse and their mechanism of action is
often unclear [7]. Centella asiatica is a widely used trad-
itional remedy in both Africa and India. The water ex-
tract of the whole plant is used by traditional healers in
Bukoba district, Tanzania for the management of both
Type I and Type 2 diabetes [8]. The plant has found
similar use in Trivandrum and Kanyakumari Districts in
India. Studies have found C. asiatica possessing signifi-
cant hypoglycemic activity in glucose tolerance test in
rabbits. It was also found not to cause hypoglycemia in
fasted rabbits compared to the standard tolbutamide [8].
The ethanolic extract showed an increased glycogen
content in the liver, comparable to the glibenclamide
standard [9]. Addtionally, the extract showed lowered
serum cholesterol and total lipid level [9,10]. Methanolic
extract was found to be more effective than ethanolic ex-
tract in lowering blood glucose [9]. However, may aspects
of basic mechanism of action of C. asiatica still remain
unclear to date. The aim of the current study is to paint a
comprehensive picture of effects C. asiatica on sucrose
breakdown and glucose absorption, insulin release, and in-
testinal enzyme functions. Our study helps to identify the
particular organ or organ system responsible for the previ-
ously seen hypoglycemic activity of this plant.Methods
Plant collection and processing
C. asiatica was collected as whole plant from University
Ayurvedic Research Centre (UARC), Jahangirnagar University,
Dhaka, Bangladesh. The plant was identified by a bo-
tanical taxonomist prior to further processing and a
voucher specimen was deposited at the National Hebar-
ium at Mirpur, Dhaka, Bangladesh. The whole plant
was cleaned off of dirt and other debris and then thor-
oughly washed under running tap water. The plant was
then air-dried in an oven at 40°C and milled into a fine
powder. 100gm of this powder was then dissolved in
1 L ethanol, and shaken in an orbital shaker (550 rpm
for 48 hrs). The mixture was then filtered using a fine
muslin cloth to remove the coarse insoluble particles.
The fine particles were forced to sediment by centrifu-
gation (1500 rpm for 10 mins). The supernatant was
carefully pipetted out and was further filtered using a
Whatman filterpaper. The filtrate was then concen-
trated by vacuum evaporation using the Soxhlet apparatus
(Electrothermal™ Soxhlet extractor, UK). The concentrate
was left in a refrigerator for 7 days to remove furtherwater, converting it into a gummy substance. This then
underwent freeze drying at −55°C to obtain a fine powder.
The fine powder extract was kept in Scott bottles along
with silica gel sachets (desiccant) until further use.
Animal handling
Both the healthy and Type 2 diabetic rats (Long Evan type)
were bred in the animal house of the Department of Phar-
macy Practice, North South university. The healthy rats
weighted about 180-220 gm while the Type 2 diabetic rats
weighed about 160-180 gm at the time of the experiment.
All test animals were kept in the North South University
Animal house at an ambient temperature of 22 ± 5°C and
humidity of 50-70%. 12 hrs day-night cycle was maintained
to avoid fluctuations in the circadian rhythm. Standard rat
pellets and filtered drinking water were made available to
the test animals ad libitum throughout the experiment
apart from the period of fasting prior to certain tests. Dur-
ing fasting only water was given. During most experimen-
tal period, the rats were kept in translucent plastic cages
with wood shavings provided as bedding. Animals under-
going fasting were placed in grilled bottomed cages, with
no bedding, to prevent corpophagy. The designed experi-
mental protocol was designed and subsequently approved
by the Ethics Committee on Animal Research, North
South University, following the “Revised guide for the care
and use of laboratory animals by American Physiological
Society” [11].
Diabetes induction
Type 2 diabetes was induced in the rats by an intraperito-
neal injection of streptozotocin (STZ) in citrate buffer so-
lution at a dose of 90 mg/kg. Rat new-borns, less than of
48 hrs age weighing 7 gm were chosen for the procedure.
Experiments were conducted three months after the STZ
injection. The type 2 diabetic rats were selected for the ex-
periment after conducting an oral glucose tolerance test
(OGTT) and only the diabetic model rats with blood glu-
cose levels of 8–12 mmol/L under fasting conditions were
selected for the experiments [12].
Acute effects of ethanolic extracts of C. asiatica on
glucose homeostasis
To evaluate effects on fasting blood glucose, the C. asia-
tica extract (250 mg/kg, 500 mg/kg and 1000 mg/kg)
was suspended in distilled water and orally administered
to 12 h fasted rats. The control animals received an
equal volume of distilled water.
Effects on glucose tolerance were similarly evaluated by
administration of C. asiatica extracts together with glucose
(2.5 g/10 ml per kg body weight) after a fasting period of
12 h. Control group received only glucose solution.
In either cases blood was collected from the tail vein,
serum separated by centrifugation and stored at −22°C
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GOD-PAP method [13] (glucose kit, Randox™, UK).
To evaluate chronic effects of C. asiatica, type 2 diabetic
rats were given extract at 250, 500, 1000 mg/kg doses by
gavage, twice daily for 28 d. Control rats were similarly ad-
ministered water alone (10 ml/kg body weight). Blood
samples were collected from the cut tip of the tail at the
times indicated in the figures. Serum was separated by
centrifugation, stored and analysed as mentioned above.
Effects of C. asiatica on plasma Insulin
Blood was drawn from Type 2 diabetic rats, 1 hr after
administration of C. asiatica. The amount of insulin re-
leased from the pancreas in-vivo, was determined using,
Rat Insulin ELISA Kit (Crystal Chem™, USA).
Effects of C. asiatica on Insulin secretion from isolated
pancreatic Islets
Pancreatic islets were isolated by collagenase digestion with
minor modifications as previously described [14]. The
amount of insulin released from the isolated islets was de-
termined by, Rat Insulin ELISA Kit (Crystal Chem™, USA).
Effects of C. asiatica on liver glycogen content
Breifly, the liver was weighed and finely homogenized
with 20 ml of 5% trichloroacetic acid (TCA). The pro-
teins precipitated, which was filtered off, and the clear
filtrate was analysed for glycogen. The liver glycogen
content was determined following the anthrone method
as described previously [15].
Effects of C. asiatica on intestinal glucose absorption
An in-situ intestinal perfusion technique [16] was used to
determine the effect of C. asiatica intestinal absorption of
glucose in 36 h fasted non-diabetic rats anaesthetized
using Ketamine (80 mg/kg). Ethanol extract of C. asiatica
(5 mg/mL, 10 mg/ml, 20 mg/mL equivalent to 0.25 mg/
kg, 0. 5 g/kg, 1 g/kg) was suspended in Krebs Ringer buf-
fer, along with glucose (54 g/l). These were passed through
rat pyloris via a butterfly cannula and the perfusate col-
lected by means of a tube inserted at the end of ileum.
The control group was perfused with Krebs Ringer buffer
along with glucose only. Perfusion was carried out at a
rate of 0. 5 ml/min for 30 min at 37°C. The results were
presented as percentage of absorbed glucose, calculated
from the percentage change in the amount of glucose in
solution before and after the perfusion.
Effects of C. asiatica on sucrose absorption from the gut
The effect of C. asiatica on sucrose absorption from gas-
troinstestinal was assayed by determining the un-
absorbed sucrose content following oral sucrose load by
Six-Segment Study as described by Hannan et al. [17].
12 h fasted, type 2 diabetic rats were administered 50%sucrose solution per oral (2.5 g/kg body mass) along
with three doses of C. asiatica (250 mg/kg, 500 mg/kg,
1000 mg/kg) and equal volume of water for control.
Blood was sampled at the following time intervals, 30,
60, 120 and 240 min, after sucrose load for the quantifi-
cation of blood glucose. At these time intervals, some of
the rats were sacrificed for determining unabsorbed su-
crose contents of the GI tract. The GI tract was excised
and separated into six segments: the stomach, the upper
20 cm, middle and lower 20 cm of the small intestine, the
caecum and the large intestine. Each segment was rinsed
with acidified ice-cold saline followed by centrifugation at
3000 rpm (1000 g) for 10 min. The supernatant was pip-
ette out and boiled for 2 h, in sulphuric acid, to hydrolyse
the sucrose. The sulfuric acid was later neutralized by
NaOH solution. Both plasma glucose concentration, and
the amount of glucose released from residual sucrose in
the GI tract was determined. The GI sucrose content was
calculated from the amount of liberated glucose [18].Effects of C. asiatica on gut motility
GI motility was determined by means of BaSO4 milk fol-
lowing the previously described method of Chattarjee [19].
BaSO4 milk was prepared by mixing BaSO4 as 10% (w/v) in
0.5% carboxy methyl cellulose to form a suspension. The
ethanol extract was administered per oral, 1 hr before the
oral administration of BaSO4 milk. Control group was ad-
ministered distilled water only (10 ml/kg). Rats belonging
to all groups were sacrificed 15 mins after BaSO4 adminis-
tration. The distance travelled by BaSO4 milk was mea-
sured, and represented as a percentage of total length of
the small intestine (from pylorus to ileocaecal junction).
Effects of C. asiatica on intestinal disaccharidase enzyme
activity
The assay was conducted following the procedure as de-
scribed previously by Hannan et al. [20]. The ethanol ex-
tract of C. asiatica (250, 500 and 1000 mg/kg) was
administered by gastric gavage to 20 hrs fasted non-
diabetic rats. After 60mins, the rats were sacrificed and the
small intestine was isolated, cut longitudinally, rinsed with
ice-cold saline and homogenized in 10 ml saline (0.9%
NaCl). Aliquots of homogenate were incubated with
40 mM-sucrose at 37°C for 60 min. The amount of protein
was determined by DC™ Protein Kit (Bio Rad, USA). Disac-
charidase activity was determined from the glucose con-
centration converted from sucrose as μmol/mg protein/h.
Effect of C. asiatica on body mass, food and water intake
of type 2 diabetic rats
The rats kept for chronic study were provided with suffi-
cient amounts of food and water for one day. At the end
of the day, the mass of food and volume of water intake
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also monitored at periods as shown in the graph.
Effects of C. Asiatica on organ weight ratio of liver and
pancreas
The animals used on the chronic study were sacrificed by
cervical dislocation at the end of the study period and the
liver and pancreas were excised. They were cleaned of fats,
and were kept moist at all times keeping them in normal
saline (0.9% of NaCl). The wet mass of the organs were
immediately weighed using a digital balance. The weight
of the pancreas was expressed as mg/100 gm of body
weight while the weight of the live was represented as gm/
100 gm of body weight, as shown in the graphs.
Chronic effects of ethanolic extracts of C. asiatica on
serum lipid profile of type 2 diabetic model rats
To assess chronic effects of C. asiatica, type 2 diabetic
model rats were ethanol extract at three dosages
(250 mg/kg, 500 mg/kg and 1000 mg/kg) by gastric ga-
vages, twice daily for 28 d. Control rats were adminis-
tered only distilled water of similar volume. Blood
samples were collected from the tail vein, at times, indi-
cated in the graphs. Serum was separated by centrifuga-
tion and stored at 22°C until further analysis.
Effect of C. asiatica on jejunal nutrient absorption by
glucose dialysis-tube retardation assay
Dry, precut dialysis sacs (inflated diam. approx. 16 mm,
length = 30 cm, Sigma Aldrich™, USA) were soaked in 1 g
sodium azide/L. The bag was loaded with 6 mL sodium
azide (1 gm/L) and 36 mg glucose alone (the control sac)
or after addition of fine powder of C. asiatica. The dry fi-
brous powder was wetted by an aqueous solution of so-
dium azide (1 g/L) for 14 h prior to the experiment. The
sacs were closed at the ends and hung in a solution of
100 mL of sodium azide (1 g/L) and then placed in a
stirred bath at 37°C for 1 hr. At 30 and 60mins time inter-
val, 2 mL of the dialysate was analyzed for glucose by the
GOD-PAP method as previously described.
The effect of fiber on nutrient absorption was indi-
cated by the glucose dialysis retardation index:
−
Total glucose diffused from sac containing fiber  100
Total glucose diffused from sac containing no fiber present
 
Effect of C. asiatica on α-amylase activity
The effects of C. asiatica powder on starch digestibility was
determined as a function of time in a fiber-enzyme-starch
mixture system using a dialysis membrane with a cutoff
molecular weight of 12,000 da (inflated diam. approx.
16 mm, length = 30 cm, Sigma Aldrich™, USA) as previously
described with minor modifications [15]. A solution wasprepared by mixing 0.2 g of powdered C. asiatica and
0.04 g α-amylase (obtained from human saliva, Sigma
Aldrich™ USA) in 10 ml of potato starch solution (4 g/
100 ml) was dialyzed in 200 ml deionised water at 37°C.
Following the incubation period, 10, 30, 60, and 120 min,
glucose concentration in the dialysate solution was assayed
using the GOD-PAP method as described previously. The
control was run without the addition of powder.
Determination of glucose-adsorption capacity
The assay was conducted following the procedure by Ou
et al. [21], where the glucose-adsorption ability (mM/mol/
gm) was measured by mixing 1 g of insoluble plant powder
or Carboxymethyl cellulose (CMC) with 100 mL of glucose
solution at a constant temperature of 37°C for 6 hrs. This
was then followed by centrifugation at 3500 rpm for
15 min. Glucose concentration in the supernatant was
assayed using GOD-PAP method as previously described.
Statistical analysis
Statistical tests were conducted using Statistical Package
for Social Science Software (SPSS) ver. 20 (IBM, Inc.,
Chicago, IL, USA). Results are presented as means ± SEM.
Data from experimental groups were compared using un-
paired Student’s t test and the Mann-Whitney U test, as
required. Experiments with data being collected at several
time intervals, were analyzed using repeated measures
ANOVA followed by Bonferroni adjustment ensuring an
error margin within ≤5%. One-way ANOVA was carried
out and pair-wise comparisons were made with the con-
trol group using Dunnett’s test to maintain an acceptable
error margin of 5%. A two-tailed P value of <0.05 was con-
sidered statistically significant.
Results
Acute and chronic effects of C. asiatica on glucose
homeostasis
Oral administration of C. asiatica, at any doses, did not
alter the hyperglycaemic condition of fasted type 2 dia-
betic rats (Figure 1). The extract, at 1000 mg/Kg dose,
improved glucose homeostasis at 60 min and 120 min,
when administered along with glucose load (p < 0.05;
Figure 2). However, the extract did not show any effect
on plasma insulin level (Figure 3).
After a 28 days chronic study of C. asiatica (three
doses, administered twice daily) on type 2 diabetic rats,
1000 mg/Kg dose showed significant reduction in serum
glucose level (p < 0.05; Figure 4).
Effect of C. asiatica on serum glucose after sucrose load
All the doses of C. asiatica showed a significant (p < 0.05)
suppression of serum glucose level at 30 min compared to
control, where peak serum glucose was observed after
administration of sucrose load. 1000 mg/Kg dose of























Figure 1 Effects of ethanol extract of C. asiatica (CA) on fasting
blood glucose level in type 2 diabetic rats. Values are means and
standard deviations represented by vertical bars (n = 10). Fasted rats
were given ethanol extract of C. asiatica (250 mg/kg, 500 mg/kg,
and 1000 mg/kg body weight) or Glibenclamide (GC) (0.5 mg/Kg) or
only water (control) by oral administration. Mean values marked with
an asterisk (*) were significantly different from those of respective
control rats (p < 0.05) (derived from repeated-measures ANOVA and
adjusted using Bonferroni correction).


























Figure 2 Effects of ethanol extract of C. asiatica (CA) on
glucose tolerance in type 2 diabetic rats. Values are means and
standard deviations represented by vertical bars (n = 11). Fasted rats
were given ethanol extract of C. asiatica (250 mg/kg, 500 mg/kg,
and 1000 mg/kg body weight) or Glibenclamide (GC) (0.5 mg/Kg) or
only water (control) by oral administration with glucose (2.5 g/kg
body weight). Mean values marked with an asterisk (*) were
significantly different from those of respective control rats (p < 0.05).




























Figure 3 Effects of ethanol extract of C. asiatica (CA) on plasma
insulin level in type 2 diabetic rats. Values are means and
standard deviations represented by vertical bars (n = 8). Rats were
given ethanol extract of C. asiatica (250 mg/kg, 500 mg/kg, and
1000 mg/kg body weight) or Glibenclamide (GC) (0.5 mg/Kg) or
only water (control) by oral administration. Mean values marked with
an asterisk (*) were significantly different from those of respective
control rats (p < 0.05) (derived from repeated-measures ANOVA and
adjusted using Bonferroni correction).
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level at 60 min too (Figure 5).
Effect of C. asiatica on intestinal glucose absorption
1000 mg/Kg doses of C. asiatica extract, when perfu-
sated with glucose, showed significant (p < 0.05) reduc-
tion in the percentage of glucose absorption during most
of the perfusion period (Figure 6).
Effect of C. asiatica on unabsorbed sucrose content in the
gastrointestinal tract
Upon oral administration of sucrose along with C. asia-
tica (1000 mg/Kg), significant amount of unabsorbed
sucrose was remained in the stomach, upper, middle,
and lower intestine at 30 min and 1 h. This amount of
residual sucrose remained significant in caecum and
large intestine till 4 h (p < 0.05; Figure 7).
Effect of C. asiatica on gut motility and intestinal
disaccharidase enzyme activity
C. asiatica extract increased the gastrointestinal motility
significantly (p < 0.05) at both 500 mg/Kg and 1000 mg/
Kg doses. However, the extract showed significant (p >
0.05) inhibition of disaccharidase enzyme activity only at




























Figure 4 Effects of ethanol extract of C. asiatica (CA) on fasting serum glucose level in type 2 diabetic rats after 28 days of feeding.
Values are means and standard deviations represented by vertical bars (n = 10). Fasted rats were given ethanol extract of C. asiatica (250 mg/kg,
500 mg/kg, and 1000 mg/kg body weight) or Glibenclamide (GC) (0.5 mg/Kg) or only water (water control, WC) by oral administration for a
period of 28 days. Mean values marked with an asterisk (*) were significantly different from those of respective control rats (p < 0.05) (derived
from repeated-measures ANOVA and adjusted using Bonferroni correction).


























Figure 5 Effects of ethanol extract of C. asiatica (CA) on serum
glucose after the sucrose load in type 2 diabetic rats. Rats were
fasted for 20 h and administered orally with a sucrose solution
(2.5 g/kg body weight) with or without ethanol extract of C. asiatica
(250 mg/kg, 500 mg/kg, and 1000 mg/kg body weight) or Acarbose
(ACB) (200 mg/Kg) or only water (control). Values are means and
standard deviations represented by vertical bars (n = 8). Mean values
marked with an asterisk (*) were significantly different from those of
respective control rats (p < 0.05) (derived from repeated-measures
ANOVA and adjusted using Bonferroni correction).



























Figure 6 Effects of ethanol extract of C. asiatica (CA) on
intestinal glucose absorption in type 2 diabetic rats. Rats were
fasted for 36 h and the intestine was perfused with glucose (54 g/l)
with (treated group) or without (control group) ethanol extract of
C. asiatica (5 mg/ml, 10 mg/ml, and 20 mg/ml; each subject
received 15 ml of perfusion). Values are means and standard
deviations represented by vertical bars (n = 9). Mean values marked
with an asterisk (*) were significantly different from those of
respective control rats (p < 0.05) (derived from repeated-measures
ANOVA and adjusted using Bonferroni correction).
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Figure 7 Effects of ethanol extract of C. asiatica (CA) on gastrointestinal sucrose content after oral sucrose loading in type 2 diabetic
rats. Rats were fasted for 20 h before the oral administration of a sucrose solution (2.5 g/kg body weight) with (treated group) or without
(control group) ethanol extract of C. asiatica (250 mg/kg, 500 mg/kg, and 1000 mg/kg body weight). Values are means and standard deviations
represented by vertical bars (n = 8). Mean values marked with an asterisk (*) were significantly different from those of control rats (p < 0.05)
(derived from repeated-measures ANOVA and adjusted using Bonferroni correction).
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islets
C. asiatica extract, at any dose, did not induce any stimu-
latory activity on insulin secretion from isolated islets in
the presence of both 3 mM and 11 mM glucose (Table 1).
Chronic effect of C. asiatica on Liver glycogen, organ
weight, food habit, and serum lipid profile
After the 28 days long study of C. asiatica (three doses,
administered twice daily) on type 2 diabetic rats, nosignificant changes were seen in the liver glycogen con-
tent, liver weight, and pancreas weight (Figure 9). How-
ever, significant reductions in body weight, food intake,
and water intake were observed at the end of the study
(p<0.05; Figure 10).
C. asiatica extract of 1000 mg/Kg dose improved
serum lipid profile of type 2 diabetic rats after 28 days of
twice daily oral feeding. It decreased the level of serum
triglyceride, low density lipoprotein (LDL), and choles-


























































Figure 8 Effects of ethanol extract of C. asiatica (CA) on
a) gastrointestinal motility (by BaSO4 traversed) and
b) intestinal disaccharidase activity in type 2 diabetic rats.
Rats were fasted for 20 h before the oral administration of ethanol
extract of C. asiatica (250 mg/kg, 500 mg/kg, and 1000 mg/kg body
weight) or water (control). Enzyme activity was determined and
BaSO4 was administered at 60 min. Motility was measured over the
following 15 min. Acarbose (ACB) (200 mg/Kg) and Loperamide
(LPM) 5 mg/Kg) & Domperidone (DMP) (10 mg/Kg) were used as
reference controls for disaccharidase activity test and gastrointestinal
motility test respectively. Values are means and standard deviations
represented by vertical bars (n = 12). Mean values marked with an
asterisk (*) were significantly different from those of diabetic control
rats (p < 0.05) (derived from repeated-measures ANOVA and adjusted
using Bonferroni correction).
Table 1 Effect of ethanolic extract of CA (Centella
asiatica) on insulin secretion from isolated rat islets
Group Insulin secretion (ng/mg islet protein)
Glucose: 3 mM Glucose: 11 mM
Control 2.99 (2.65-4.27) 5.41 (4.91-9.27)*
CA 20 μg/ml 2.78 (2.19-3.56) 5.03 (4.24-8.54)
CA 40 μg/ml 3.09 (2.43-3.82) 5.11 (4.39-7.98)
CA 80 μg/ml 2.85 (2.07-3.69) 5.24 (4.78-8.61)
Glibenclamide (10 μg/l) 5.89 (4.34-6.95)* 8.92 (7.67-9.86)*
Isolated rat islets were incubated for 60 min with ethanol extract of Centella
asiatica (10, 20, and 30 mg/ml) in the presence of 3 or 11 mM glucose. Data
are presented as median (range), n=5. Mann–Whitney U-test was used to
evaluate statistical significance. *p < 0.05 compared with control (3 mM
glucose without extract).
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Moreover, the extract increased the level of high density
lipoprotein (HDL) significantly (p < 0.05; Figure 11).
Effect of C. asiatica powder on In vitro glucose dialysis
retardation index (GDRI)
C. asiatica powder at different doses reduced the
amount of glucose present in the dialysate. However, it
was significant only for 1000 mg powder group; GDRI
45.8% and 48.54% at 30 min and 60 min respectively
(p < 0.05; Table 2).
Effect of C. asiatica powder on α-amylase activity
The effect of C. asiatica powder on starch digestibility
was determined by the alteration in the glucoseconcentration in the dialysate with time. There was no
significant change, compared to control, in the glucose
content at 10 min. However, the glucose content in the
dialysate was significantly increased, compared to con-
trol, at 30 min, 1 h, and 2 h (p < 0.05; Table 3).
Effect of C. asiatica powder on In vitro glucose adsorption
capacity
C. asiatica powder showed high capacity of glucose ad-
sorption in the presence of different levels of glucose in
the solution. This activity of glucose adsorption was
found to persist from higher level of glucose to even
very low level of glucose present in the solution
(Table 4).
Discussion
C. asiatica is a plant, native to the Indian Subcontinent,
continental Asia, Australia and Papua New Guinea [22].
It is indigenously used to treat a wide range of patho-
logical conditions including diabetes, which provides a
solid ground for our current study [8-10]. Additionally,
unpublished, preliminary screening data, of this plant,
showed highly promising hypoglycemic activity. How-
ever, there are no reported studies on tissue level mech-
anism of action of C. asiatica. Studies have established
that hyperglycemic states, during diabetes, is the initiator
of diabetic tissue damage [23]. Cells damaged by hyper-
glycemia cannot maintain a constant internal glucose
concentration, which results in acutely altered cellular
metabolism and long-term changes in cellular macro-
molecular content [24-26]. Postprandial glucose spike
causes perturbation in endothelial cell function [27,28],
and increased blood coagulation [29]. Hyperglycemic
states also increases products of glycosylation, which has
a significant influence in development of diabetic in-
duced vascular disease [30]. Therefore, management of
hyperglycemic states is an important method of diabetes
control. The basic mechanism of actions of commonly
































































































Figure 9 Effects of ethanol extract of C. asiatica (CA) on body weight, average food intake, and average water intake in type 2 diabetic
rats after 28 days of feeding. Values are means and standard deviations represented by vertical bars (n = 10). Fasted rats were given ethanol
extract of C. asiatica (250 mg/kg, 500 mg/kg, and 1000 mg/kg body weight) or Glibenclamide (GC) (0.5 mg/Kg) or only water (control) by oral
administration for a period of 28 days. Mean values marked with an asterisk (*) were significantly different from those of respective control rats
(p < 0.05) (derived from repeated-measures ANOVA and adjusted using Bonferroni correction).















































































































Figure 10 Effects of ethanol extract of C. asiatica (CA) on liver glycogen, liver weight, and pancreas weight in type 2 diabetic rats after
28 days of feeding. Values are means and standard deviations represented by vertical bars (n = 10). Fasted rats were given ethanol extract of
C. asiatica (250 mg/kg, 500 mg/kg, and 1000 mg/kg body weight) or Glibenclamide (GC) (0.5 mg/Kg) or only water (water control, WC) by oral
administration for a period of 28 days. Mean values marked with an asterisk (*) were significantly different from those of respective control rats
(p < 0.05) (derived from repeated-measures ANOVA and adjusted using Bonferroni correction).
















































































































Figure 11 Effects of ethanol extract of C. asiatica (CA) on serum lipid profile (TG, Cholesterol, HDL, and LDL) in type 2 diabetic rats
after 28 days of feeding. Values are means and standard deviations represented by vertical bars (n = 10). Fasted rats were given ethanol extract
of C. asiatica (250 mg/kg, 500 mg/kg, and 1000 mg/kg body weight) or Glibenclamide (GC) (0.5 mg/Kg) or only water (control) by oral
administration for a period of 28 days. Mean values marked with an asterisk (*) were significantly different from those of respective control rats
(p < 0.05) (derived from repeated-measures ANOVA and adjusted using Bonferroni correction).
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cose utilization, inhibition of glucose absorption, and in-
hibition of carbohydrate digestion [31]. In our current
study, we have employed techniques, which will suggest
one or more of the aforementioned modes of action.
Altered lipid metabolism is a hallmark of type 2 dia-
betes induced dyslipidemia, which is characterized by re-
duced HDL and increased LDL, triglycerides, and total
cholesterol [32]. Hyperglycemia and altered lipid status,
in tandem, poses a significant threat of cardiovascular
complications in diabetic patients. Unattended hyperlip-
idemia might give rise to both micro and macro vascular
complications in type 2 diabetic patients [33]. Therefore,
alleviated lipid profile in patients might improve diabetes
induced secondary complications. Type 2 diabetic rats
treated with 1000 mg/kg of C. asiatica extract showedTable 2 Retarding effect of insoluble fibre of CA on the gluco





CA 250 mg 0.83 ± 0.19 30.25
CA 500 mg 0.76 ± 0.12 35.29
CA 1000 mg 0.65 ± 0.09* 45.38
CMC 1000 mg 0.62 ± 0.11* 42.86
Control 1.19 ± 0.21 0
Data are presented as Mean ± SEM (n = 7). Glucose dialysis retardation index = contro
significantly different from those of respective control groups (p < 0.05) (derived frommarked improvement in serum lipid profile at the end of
our 28 days study period.
Type 2 diabetic patients have a higher incidence of
obesity. It is also characterized by polyphagia and poly-
dipsia [34]. By the end of our study period, C. asiatica
treated Type 2 diabetic rats returned to a normal body
weight and exhibited food and water intake comparable
to healthy rats.
Studies have shown that blood glucose level in the
upper normal range is a probable risk factor for cardio-
vascular disease, a condition, chronic in Type 2 diabetic
patients [35]. In our studies, fasting blood glucose
remained unaffected in Type 2 diabetic rats in all groups
apart from the “Glibenclamide” control group. In glucose
tolerance test, the peak glucose concentration after glu-
cose challenge in C. asiatica treated group at 1000 mg/kgse movement (glucose dialysis retardation index)
Dialysis for 60 min




1.15 ± 0.15 32.75
1.09 ± 0.06 36.26
0.88 ± 0.12* 48.54
0.83 ± 0.07* 51.46
1.71 ± 0.14 0
l (100%) – fibre (% of control value). Mean values marked with an asterisk (*) were
repeated-measures ANOVA and adjusted using Bonferroni correction).
Table 3 Effect of insoluble fibre of CA on starch
digestibility
Treatment Glucose in dialysate (μmol/l)
10 min 30 min 60 min 120 min
CA 250 mg 1.72 ± 0.09 4.05 ± 0.15 13.6 ± 1.23 21.7 ± 4.10
CA 500 mg 1.81 ± 0.11 4.56 ± 0.42* 14.3 ± 2.32 23.50 ± 5.20*
CA 1000 mg 1.85 ± 0.15 4.88 ± 0.50* 15.89 ± 2.11* 26.45 ± 4.83*
CMC 1000 mg 1.91 ± 0.21 4.94 ± 0.34* 16.09 ± 2.31* 26.57 ± 5.34*
Control 1.52 ± 0.06 3.87 ± 0.12 12.5 ± 1.23 19.5 ± 3.73
Data are presented as Mean ± SEM (n = 4). Values represent the glucose
concentration (μmol) in dialysate. Mean values marked with an asterisk (*) were
significantly different from those of respective control groups (p < 0.05) (derived
from repeated-measures ANOVA and adjusted using Bonferroni correction).
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glucose concentration was significantly lower than the
250, 500 mg/kg treated group or the control group. Two
of the above findings reinforces previous claims about C.
asiatica having anti-hyperglycemic activity without indu-
cing hypoglycemia [8,9]. Therefore, it might be devoid of
one of the key flaws in many of the currently prescribed
anti-diabetic medications [36].
To further ascertain, mechanism of anti-diabetic ac-
tion, we measured the plasma insulin level of the test
animals and found no significant increase in insulin se-
cretion on C. asiatica administration, at all doses. This
preliminary finding was further strengthened by a simi-
lar lack of activity shown by C. asiatica on isolated rat
islets. Furthermore, liver glycogen content remained un-
altered with respect to control group. Therefore, in-
creased insulin secretion or increased sensitivity to
insulin action can both be ruled out. It is to be noted
that, wet mass of both liver and pancreas in control and
treated groups did not significantly differ. Regeneration
of pancreatic β-cell mass and enhanced glucose
utilization can be preliminary ruled out [37].
An in situ intestinal perfusion of the GI tract shows
marked reduction in glucose absorption. In BaSO4 GI
motility assay, intestinal motility was found to be signifi-
cantly higher. Numerous published results have shown
the ability of complex carbohydrate, high molecularTable 4 Glucose adsorption capacity of insoluble fibre of CA
Treatment G
5 mmol/l 10 mmol/l
CA 250 mg 0.03 ± 0.01a 0.91 ± 0.11a
CA 500 mg 0.06 ± 0.01b 1.87 ± 0.43b
CA 1000 mg 0.08 ± 0.02c 2.67 ± 0.61c
CMC 1000 mg 0.08 ± 0.01c 2.71 ± 0.45c
Data are presented as Mean ± SEM (n = 4). Data represent the millimoles of glucos
(5-200 mmol/l). Glucose bound = (glucose concentration of original solution - gluco
solution ÷ weight of dietary fibre. Mean values in the same column marked with di
were found to be statistically similar to the positive control were denoted as “c”; the
different from both the positive control and themselves; these values represent non
adjusted using Bonferroni correction).weight, and viscous, soluble dietary fibers, to retard glu-
cose absorption [38-40]. C. asiatica has been said to
contain oligosaccharide centellose, resin and large
amounts of insoluble dietary fibers [41]. Dietary fibers
often provide a greater barrier to diffusion caused due to
its high viscosity and ability to bind to glucose [38].
Dietary fibers are capable of significantly reducing the
transit time in GI Tract of ingested food [42]. Reduced
transit time can be translated as lesser time available for
di-and polysaccharides in the meal to be digested and
absorbed [43]. It logically follows a lower glucose peak
concentration after the meal.
Six Segment test showed significantly higher amount
of sucrose in stomach, upper, middle and lower intestine
in C. asiatica administered groups. The latter three part
of GI are most important for absorption of nutrients in-
cluding sugars [44]. Disaccharides in its own form does
not get absorbed due to lack to sucrose carriers, as car-
riers monosaccharides only are present in the GI tract
[45]. Therefore, it is imperative that disaccharides get
converted to monosaccharides first for absorption.
Higher sucrose content in the GI Tract clearly reflects a
reduced sucrose digestion throughout the GI Tract. This
in turn, is shown by a significantly higher concentration
of sucrose reaching the large intestine and caecum,
which eventually remains unabsorbed and egested with
faeces.
In the intestinal disaccharidase activity and the α-
amylase activity assay, C. asiatica was shown to have re-
duced the catabolism of sucrose and starch respectively.
Since complex carbohydrates and disaccharides have
first to be broken down into simpler monosaccharides
[45], it follows that any inhibition of this catabolic
process would retard sugar absorption, which would in
turn, be shown as a lower glycemic peak. However, the
precise mechanism of this inhibitory action remains to
be studied.
In-vitro studies involving fiber binding assays clearly
demonstrated glucose being bound by dietary fibers avail-
able in C. asiatica even at very low glucose concentrations.
Glucose are carried by specific transport proteins [45].in different concentrations of glucose
lucose bound (mmol/g)
50 mmol/l 100 mmol/l 200 mmol/l
4.88 ± 0.93a 9.23 ± 1.02a 19.43 ± 3.37a
6.78 ± 2.10b 13.89 ± 3.67b 23.88 ± 4.87b
8.93 ± 1.98c 16.75 ± 4.12c 29.94 ± 7.50c
9.32 ± 2.09c 17.81 ± 3.78c 30.97 ± 6.88c
e bound by each gram of the CA extract at different glucose concentrations
se concentration when the adsorption reached equilibrium) × volume of
fferent letters (a, b, and c) were significantly different at p < 0.05 (Values which
y present strong fibre binding. Values denoted by “a” and “b” were statistically
significant fibre binding) (derived from repeated-measures ANOVA and
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of these transport proteins. This fully validates our initial
findings in the gut perfusion experiments, which too
showed a hindrance in glucose absorption. This now can be
fully attributed to glucose-fiber binding in Centella asiatica
whole plant powder.
Further research is underway, in our labs, for identify-
ing the active molecules responsible for inhibiting α-
amylase and disaccharidase. We also intend to study the
protein transporters, most affected by the active com-
pound, via radio-ligand binding assay. In conclusion, we
report absence of enhanced insulin secretion in C. asia-
tica treated animal groups. No significant improvement
was seen in liver glycogen deposition either. Findings in
previous studies reporting anti-hyperglycemic activity in
C. asiatica, can be probably attributed to reduced carbo-
hydrate breakdown, glucose-fiber binding, thus, and
overall reduced glucose absorption through the GI tract.
Furthermore, on chronic intake, it has ability to lower
harmful LDL and Cholesterol in animal models while
elevating the beneficial HDL. C. asiatica calls for further
attention from the scientific community to further eluci-
date its activity and establish its safety profile.
Conclusions
Our studies confirm the previous findings showing anti-
hyperglycemic action of C. Asiatica. Additionally, we
have elucidated that C. Asiatica is capable of inhibiting
absorption of glucose both by inhibition of intestinal di-
saccharidase enzymes and α-amylase and by glucose-
fibre binding. On chronic intake, it has lowers serum
LDL and Cholesterol and elevates the HDL. Therefore,
its traditional use, as mentioned above is justified and
calls for further research, to optimize its anti-diabetic
activity.
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